Abstract：Objective: To investigate the clinical efficacy of tabazole combined with glucocorticoid in the treatment of hyperthyroidism and its effect on serum procollagen type III (PCIII), beta 2-microglobulin (beta 2-MG), hyaluronic acid (HA) and albumin (ALB). Methods: 80 cases of hyperthyroidism according to simple random sampling were divided into control group and research group, 40 patients in each group. control group was treatmented with tumazole, and the research group was treatmented with tumazol and glucocorticoids. then clinical curative effect, thyroid-stimulating hormone (TSH), three free iodine thyroid glycine (FT3), free thyroxine (FT4), PCⅢ, β2-MG, HA, ALB, and adverse reactions occur between two group was compared. Results: The total effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P<0.05). TSH increased and FT3 and FT4 decreased in both groups at 3 and 6 months after treatment. TSH was higher and FT3 and FT4 were lower in the study group than in the control group at each time point. The thyroid levels of the two groups were significantly different at 3 and 6 months after treatment (P<0.05). At 3 and 6 months after treatment, PCIII, beta 2-MG and HA were decreased and ALB was increased in both groups. PCIII, beta 2-MG and HA in study group were lower than those in control group and ALB was higher than those in control group at each time point. The serum levels of PCIII, beta 2-MG, HA and ALB in two groups were significantly different at 3 months and 6 months after treatment (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Tabazole combined with glucocorticoids in the treatment of hyperthyroidism is superior to tabazole alone. It can reduce serum PC III, beta 2-MG and HA levels, promote the expression of ALB, may be an effective treatment for hyperthyroidism patients.
王勃,杨荣礼,李雷,王昭玲. 他巴唑联合糖皮质激素治疗甲状腺功能亢进的临床疗效及对血清PCⅢ β2-MG HA ALB的影响[J]. 河北医学, 2018, 24(11): 1794-1797.
WANG Bo, et al. Clinical Efficacy of Tabazole Combined with Glucocorticoid in the Treatment of Hyperthyroidism and Its Effect on Serum PC III beta 2-MG HA and ALB. HeBei Med, 2018, 24(11): 1794-1797.
[1] 王啓雄.原发性甲状腺功能亢进症38例临床分析[J].中国现代普通外科进展,2015,18(9):719. [2] 王晶,刘哲.碳酸锂联合甲巯咪唑治疗甲状腺功能亢进的临床研究[J].现代药物与临床,2015,30(11):1395~1397. [3] Journy NMY, Bernier MO, Doody MM, et al. Hyperthyroidism and cause-specific mortality in a large cohort of women[J].Thyroid,2017,27(8):1001~1010. [4] 陆伦根.肝纤维化基础和临床研究热点问题[J].实用肝脏病杂志,2016,19(1):1~3. [5] Reddy V, Taha W, Kundumadam S, et al. Atrial fibrillation and hyperthyroidism: A literature review[J]. Indian Heart J,2017,69(4):545~550. [6] 操向瑛.中药联合他巴唑治疗甲状腺功能亢进临床疗效观察及对甲状腺激素水平的影响[J].中华中医药学刊,2015,33(05):1241~1243. [7] 熊慧丽,周庆元,赵晓宏,等.甲巯咪唑联合131I治疗甲状腺功能亢进的疗效及安全性分析[J].药物评价研究,2017,40(2):245~248. [8] 王东岩.甲状腺功能亢进症的临床药物治疗探析[J].中国现代药物应用,2017,11(16):126~127. [9] Black RJ, Goodman SM, Ruediger C, et al. A survey of glucocorticoid adverse effects and benefits in rheumatic diseases: the patient perspective[J].Clin Rheumatol,2017,23(8):416~420. [10] 毕礼明,陈英兰.甲状腺功能亢进相关性肝损害认识进展[J].山西医药杂志,2015,44(9):1001~1003. [11] 林源,于军,高海燕,等.比索洛尔联合甲巯咪唑对甲状腺功能亢进症患者糖脂代谢及血清CysC、β2-MG的影响[J].中国临床研究,2017,30(9):1195~1197.
2018, Vol. 24 
冀公网安备13080202000677号